Profil bibliographique

Richard S. Finn

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

9Publications signalées

0Citations signalées

0Affiliations récentes

Les domaines associés

Cholangiocarcinoma and Gallbladder Cancer StudiesHepatitis B Virus StudiesPancreatic and Hepatic Oncology ResearchHepatocellular Carcinoma Treatment and PrognosisGallbladder and Bile Duct Disorders

Les publications récentes

Accès ouvert 2026 other OpenAlex

Data from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

Stephen L. Chan, Thomas Yau, Robin K. Kelley, Richard S. Finn et autres

AbstractPurpose: In the randomized phase 3 KEYNOTE-966 trial, first-line pembrolizumab plus chemotherapy significantly improved overall survival (OS) versus placebo plus chemotherapy for participants with advanced biliary tract cancer (BTC). This post hoc analysis investigated whether hepatitis B virus (HBV) infection affected the …

0 citations

Accès ouvert 2026 other OpenAlex

Table S4 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

Stephen L. Chan, Thomas Yau, Robin K. Kelley, Richard S. Finn et autres

Representativeness of study participants.

0 citations

Accès ouvert 2026 other OpenAlex

Table 1 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

Stephen L. Chan, Thomas Yau, Robin K. Kelley, Richard S. Finn et autres

Baseline demographics and disease characteristics by HBV infection status (ITT population).

0 citations

Accès ouvert 2026 other OpenAlex

Figure S2 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

Stephen L. Chan, Thomas Yau, Robin K. Kelley, Richard S. Finn et autres

Figure S2 shows time course of HBV DNAa and ALT levels, duration of treatment, and initiation of new antiviral therapy in participants with chronic HBV at baseline who experienced HBV reactivation during the study

0 citations

Accès ouvert 2026 other OpenAlex

Table S1 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

Stephen L. Chan, Thomas Yau, Robin K. Kelley, Richard S. Finn et autres

Baseline demographic and disease characteristics by chronic and clinically resolved HBV infection (ITT population)

0 citations

Accès ouvert 2026 other OpenAlex

Table 2 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

Stephen L. Chan, Thomas Yau, Robin K. Kelley, Richard S. Finn et autres

HBV-related outcomes in evaluable participants with HBV infectiona.

0 citations

Accès ouvert 2026 other OpenAlex

Figure S1 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

Stephen L. Chan, Thomas Yau, Robin K. Kelley, Richard S. Finn et autres

Figure S1 shows time course of HBV DNAa and ALT levels, duration of treatment, and initiation of new antiviral therapy in participants with clinically resolved HBV at baseline who experienced HBV reactivation during the study

0 citations

Accès ouvert 2026 other OpenAlex

Table S3 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

Stephen L. Chan, Thomas Yau, Robin K. Kelley, Richard S. Finn et autres

Summary of adverse events by HBV infection status (APaT population)

0 citations

Accès ouvert 2026 other OpenAlex

Table S2 from Impact of Hepatitis B Virus Infection on the Efficacy and Safety of Pembrolizumab plus Chemotherapy for Advanced Biliary Tract Cancer in the KEYNOTE-966 Study

Stephen L. Chan, Thomas Yau, Robin K. Kelley, Richard S. Finn et autres

Summary of antiviral therapy in treated participants with HBV infection who received antiviral medication during the study

0 citations

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Les publications sont interrogées à la demande dans Crossref, OpenAIRE, DOAJ, Europe PMC, HAL, DataCite, AfricArXiv, ROR et la Banque mondiale, sans clé d’accès. OpenAlex reste optionnel. Aucun service payant n’est nécessaire et aucune donnée externe n’est enregistrée en base. Consulter les sources et leurs limites.